MONACO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- First participation and first historic victory: Yacht Club de Monaco wins the 2025 Admiral’s Cup with a nail-biting finale. Led by the YCM’s vice-president, Pierre Casiraghi (Jolt 6), and Peter Harrison (Jolt 3), the two Monegasque teams dominated the Rolex Fastnet Race, the final and decisive event (coefficient 3) of the trophy, surpassing the Royal Hong Kong Yacht Club and the Yacht Club Costa Smeralda.
The always-free membership for those who love quality local companies reaches a new record. Members stand out when they use Diamond Certified companies and...
MONACO, July 29, 2025 (GLOBE NEWSWIRE) -- Black Jack 100 claimed victory in the 51st Rolex Fastnet Race in a breathtaking finale. The maxi monohull owned by Remon Vos, member of the Yacht Club de Monaco, crossed the finish line in Cherbourg on Tuesday 29 July at 00:21, after 2 days, 12 hours, 31 minutes and 21 seconds at sea. At the helm, Tristan Le Brun - member of YCM’s Captains Club - led the crew to win the Erivale Trophy, awarded to the first monohull across the line in real time.
Special streaming premiere of performance featuring the Carnegie Hall Big Band, filmed on tour at Segerstrom Center for the Arts, available for the first...
CRANSTON, Rhode Island, July 25, 2025 (GLOBE NEWSWIRE) -- Nelipak® Corporation (“Nelipak®”), un proveedor líder global de soluciones de empaque para el sector de salud para dispositivos médicos, diagnóstico, administración farmacéutica y otras aplicaciones exigentes, anunció que ha iniciado oficialmente la construcción de su nueva planta de producción de vanguardia en el Valle Verde de Costa Rica, en Alajuela. La ceremonia de colocación de la primera piedra marca un hito importante en la continua inversión de Nelipak en Costa Rica y su compromiso de apoyar el creciente ecosistema de fabricación de dispositivos médicos en la región.
Nelipak® Corporation (“Nelipak®”) has officially broken ground on its new, state-of-the-art production facility in Costa Rica Green Valley in Alajuela.
Schlieren / Zurich, Switzerland, 25 July, 2025 – Memo Therapeutics AG ("MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announced results from its Phase II clinical trial evaluating potravitug, a highly potent human BK polyomavirus (“BKPyV”)-neutralizing monoclonal antibody, for the treatment of BKPyV infection in kidney transplant recipients (“KTR”).
COSTA MESA, Calif., July 23, 2025 /PRNewswire/ -- EnGenius Technologies Inc., a leader in enterprise networking solutions, has announced the launch of the ECS2530FP, a...
Grand prize winners each take home $25,000 in prizes
CHANHASSEN, Minn., July 21, 2025 /PRNewswire/ -- Life Time (NYSE: LTH), the nation's premier healthy lifestyle...